Detalhe da pesquisa
1.
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Lung Cancer
; 108: 154-160, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28625629